Formulations for the transdermal administration of fenoldopam

Details Formulations for the transdermal administration of fenoldopam Formulations for the transdermal administration of fenoldopam

2005-11-01

2005-11-01

Dodson, Shelley A. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S400000

Reexamination Certificate

active

06960353

ABSTRACT:
Composition of matter for application to skin to administer fenoldopam by permeation through the skin, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.

REFERENCES:
patent: 3589123 (1971-06-01), Zaffaroni
patent: 3598122 (1971-08-01), Zaffaroni
patent: 3731683 (1973-05-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4031894 (1977-06-01), Urquhart et al.
patent: 4144317 (1979-03-01), Higuchi
patent: 4197297 (1980-04-01), Weinstock
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4286592 (1981-09-01), Chandrasekaran
patent: 4314557 (1982-02-01), Chandrasekaran
patent: 4321195 (1982-03-01), Weinstock
patent: 4379454 (1983-04-01), Campbell et al.
patent: 4435180 (1984-03-01), Leeper
patent: 4552872 (1985-11-01), Cooper et al.
patent: 4559222 (1985-12-01), Enscore et al.
patent: 4568343 (1986-02-01), Leeper et al.
patent: 4573995 (1986-03-01), Cheng et al.
patent: 4588580 (1986-05-01), Gale et al.
patent: 4645502 (1987-02-01), Gale et al.
patent: 4698062 (1987-10-01), Gale et al.
patent: 4704282 (1987-11-01), Campbell et al.
patent: 4705862 (1987-11-01), Labaw et al.
patent: 4725272 (1988-02-01), Gale
patent: 4746515 (1988-05-01), Cheng et al.
patent: 4756710 (1988-07-01), Bondi et al.
patent: 4764379 (1988-08-01), Sanders et al.
patent: 4781924 (1988-11-01), Lee et al.
patent: 4788062 (1988-11-01), Gale et al.
patent: 4816258 (1989-03-01), Nedberge et al.
patent: 4849226 (1989-07-01), Gale et al.
patent: 4863738 (1989-09-01), Taskovich
patent: 4865848 (1989-09-01), Cheng et al.
patent: 4888354 (1989-12-01), Chang et al.
patent: 4900555 (1990-02-01), Cheng et al.
patent: 4904475 (1990-02-01), Gale et al.
patent: 4908027 (1990-03-01), Enscore et al.
patent: 4917895 (1990-04-01), Lee et al.
patent: 4938759 (1990-07-01), Enscore et al.
patent: 4943435 (1990-07-01), Baker et al.
patent: 5000956 (1991-03-01), Amkraut et al.
patent: 5004610 (1991-04-01), Osbourne et al.
patent: 5028431 (1991-07-01), Franz et al.
patent: 5049387 (1991-09-01), Amkraut
patent: 5071656 (1991-12-01), Lee et al.
patent: 5120145 (1992-06-01), Kawahara
patent: 5122382 (1992-06-01), Gale et al.
patent: 5130139 (1992-07-01), Cormier et al.
patent: 5141750 (1992-08-01), Lee et al.
patent: 5149539 (1992-09-01), Ledger et al.
patent: 5160741 (1992-11-01), Cormier et al.
patent: 5284660 (1994-02-01), Lee et al.
patent: 5304379 (1994-04-01), Cormier et al.
patent: 5314694 (1994-05-01), Gale et al.
patent: 5342623 (1994-08-01), Enscore et al.
patent: 5378730 (1995-01-01), Lee et al.
patent: 5451407 (1995-09-01), Cormier et al.
patent: 5629019 (1997-05-01), Lee et al.
patent: 5635203 (1997-06-01), Gale et al.
patent: 5641504 (1997-06-01), Lee et al.
patent: 5656286 (1997-08-01), Miranda et al.
patent: 5686097 (1997-11-01), Taskovich et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 6238693 (2001-05-01), Luther et al.
patent: 6699497 (2004-03-01), van Osdol et al.
patent: WO 91/16041 (1991-10-01), None
patent: WO 95/01167 (1995-01-01), None
patent: WO 95/09006 (1995-04-01), None
patent: WO 96/37231 (1996-11-01), None
patent: WO 96/40259 (1996-12-01), None
patent: WO 99/15210 (1999-04-01), None
patent: WO 99/55341 (1999-11-01), None
Nancy L. Allison et al.,Clin Phamacol Ther, 41:282-288, Mar. 1987. “The effect of fenoldopam, a dpaminergic angonist, on renal hemodynamics”.
K.F. Bodmann et al.,Clinical Investigator; 72:60-64, 1993. “Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis”.
Gary W. Cleary,Topical Drug Bioavailability, Bioequivalence, and Penetration, Chapter 2, pp. 17-68, Plenum Press, 1993. “Transdermal delivery Systems: A Medical Rationale”.
Terry L. Holcslaw et al.,American Journal of Hypertension, 3(6) Part 2:120S-125S, 1990. “Clinical Experience with Itravenous Fenoldopam”.
Diane K. Jorkasky et al.,American Journal of Kidney Diseases, XIX(6):567-572, Jun. 1992. “Fenoldopam Reverses Cyclosporine-Induced Renal Vasoconstriction in Kidney Transplant Recipients”.
Victoria.M. Knepp et al,CRC Critical Reviews and Drug Carrier Systems, 4(1):13-37, (1987). “Transdermal Drug Delivery: Problems and Possibilities”.
Andrew J. Nichols et al.,American Journal of Hypertension, 3(6) Part 2:117S-119S, 1990. “The Pharmacology of Fenoldopam”.
H.P. Schuster, et al. Intensivmed, 28:348-355, 1991 “Fenoldopam improves renal dysfunction secondary to ventilation with PEEP”.
Philip W. Wertz et al,Advanced Drug Delivery Reviews, 12:1-12, 1993. “Regional variation in the structure and permeability of oral mucosa and skin”.
International Search Report dated Nov. 11, 1999, for corresponding Appln No. PCT/US99/16083.

Affiliated with

Also associated with

Rating

Formulations for the transdermal administration of fenoldopam does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations for the transdermal administration of fenoldopam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for the transdermal administration of fenoldopam will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3495135